Fsd Pharma (TSE:HUGE) has released an update.
FSD Pharma Inc. has partnered with Ingenu CRO to conduct a clinical trial on their proprietary beverage, unbuzzd™, aiming to prove its safety and effectiveness in hastening sobriety following alcohol consumption. The product, positioned for both recreational and medical markets, is part of FSD Pharma’s diverse portfolio targeting neurodegenerative, metabolic, and alcohol misuse disorders. The trial represents a critical step in validating the company’s innovation in potentially altering the rate of alcohol metabolism.
For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.
